A real life retrospective analysis of drug expenditure reveals no significant cost difference between infliximab and adalimumab in the treatment of Adult Crohn's Disease

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Lamb CA, Price M, Robinson M, Gunn MC, Thompson NP, Mansfield JC

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: Annual Meeting of the British Society of Gastroenterology

Year of Conference: 2011

Pages: A251-A252

ISSN: 0017-5749

Publisher: Gut: BMJ Publishing Group

URL: http://dx.doi.org/10.1136/gut.2011.239301.534

DOI: 10.1136/gut.2011.239301.534

Library holdings: Search Newcastle University Library for this item

ISBN:

ePrints